Dark

Check out our Level2View

AGNPF
ALGERNON PHRMCTCLS A INC
stock OTC

EOD

Jul 11, 2025

0.0397USD-19.000%(-0.0093)65,508

Pre-market

0.00USD-100.000%(-0.05)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 28, 2022

06:00AM EST Algernon Pharmaceuticals Announces Notice of Allowance for GlobeNewswire Inc

Jan 24, 2022

07:00AM EST Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as GlobeNewswire Inc

Jan 19, 2022

07:00AM EST Algernon Pharmaceuticals Files for Clinical Trial and Ethics GlobeNewswire Inc

Jan 14, 2022

08:16AM EST Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA GlobeNewswire Inc

Dec 2, 2021

07:00AM EST Algernon Pharmaceuticals Projects Full Enrollment for Phase 2 IPF GlobeNewswire Inc

Nov 30, 2021

07:00AM EST Algernon Pharmaceuticals Inc.(the Company or Algernon) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has appointed Mr. James Kinley as the Companys Chief Financial Officer (CFO), effective December 1, 2021. Mr. Kinley will report to Algernons Chief Executive Officer (CEO) Mr. Christopher J. Moreau. GlobeNewswire Inc

Nov 24, 2021

07:00AM EST Algernon Pharmaceuticals Announces Positive Feedback from U.S. FDA GlobeNewswire Inc

Nov 23, 2021

04:01PM EST Algernon Pharmaceuticals Inc. (Algernon or the Company) (CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF), a clinical stage pharmaceutical development company, announces that effective November 24, 2021, the Company will consolidate its Class A common shares (the Common Shares) on a one-hundred (100) to one (1) basis (the Consolidation). GlobeNewswire Inc

Nov 19, 2021

07:00AM EST Algernon Announces Positive Feedback on its Planned Phase 1/2a DMT GlobeNewswire Inc

Nov 17, 2021

04:14PM EST Algernon Pharmaceuticals Announces Share Consolidation GlobeNewswire Inc

Nov 1, 2021

07:00AM EDT Algernon Pharmaceuticals Establishes 6 hours as Optimum Treatment GlobeNewswire Inc

Oct 21, 2021

07:00AM EDT Algernon Pharmaceuticals Announces Receipt of CAD$2M Cash Refund GlobeNewswire Inc

Oct 18, 2021

01:37PM EDT Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation Benzinga

Oct 13, 2021

04:25PM EDT There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are Benzinga

07:00AM EDT Algernon Files Meeting Request with MHRA for Use of DMT in Phase GlobeNewswire Inc

Oct 8, 2021

07:00AM EDT Algernon Pharmaceuticals Files U.S. FDA Pre-IND Meeting Request GlobeNewswire Inc

Sep 22, 2021

07:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, is pleased to announce that Dr. Mark Williams has been appointed as a member of the Board of Directors, replacing Michael Sadhra who has resigned from the board to pursue other business ventures. GlobeNewswire Inc

Sep 20, 2021

07:00AM EDT Algernon Pharmaceuticals Announces Plans for a Phase 2 Ifenprodil GlobeNewswire Inc

Sep 13, 2021

01:37PM EDT Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics Benzinga

Sep 9, 2021

11:47AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau will be delivering the Keynote Presentation at the Microdose Virtual 2021 The DMT Conference: A Molecular Masterclass. GlobeNewswire Inc

07:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce that Harry Bloomfield, QC. has been appointed as a new member of the Board of Directors and has been elected Chairman of the Board. GlobeNewswire Inc

Sep 7, 2021

07:30AM EDT Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons GlobeNewswire Inc

Aug 30, 2021

09:35AM EDT Microdose Psychedelic Insights Presents the Upcoming DMT GlobeNewswire Inc

Aug 11, 2021

07:00AM EDT Algernon Pharmaceuticals Announces Small Cell Lung Cancer GlobeNewswire Inc

Aug 9, 2021

08:26PM EDT Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies Benzinga

07:00AM EDT Algernon Pharmaceuticals Announces Exclusive Licensing Agreement GlobeNewswire Inc

Aug 3, 2021

02:25PM EDT Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies Benzinga

Jul 7, 2021

07:30AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, announces that it has reached 70% of its enrollment target for its Phase 2 clinical study of its re-purposed drug NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis (IPF) and chronic cough. GlobeNewswire Inc

Jul 6, 2021

08:30AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, announces that it will not be advancing Ifenprodil into a Phase 3 clinical study for COVID-19. GlobeNewswire Inc

Jun 21, 2021

10:22AM EDT Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform Benzinga

Jun 17, 2021

07:00AM EDT Algernon Pharmaceuticals Targets First Human Study of its GlobeNewswire Inc

Jun 3, 2021

07:00AM EDT Algernon Pharmaceuticals Launches Pancreatic Cancer Clinical GlobeNewswire Inc

May 27, 2021

07:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) is pleased to highlight an independent research study from the University of Szeged in Hungary describing the use of N,N-dimethyltryptamine (DMT) in improving outcomes in a rat stroke model. A preprint of the study was published on May 20, 2021 in the journal Neuropharmacology. GlobeNewswire Inc

May 17, 2021

07:00AM EDT Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA GlobeNewswire Inc

May 12, 2021

07:15AM EDT Algernon Pharmaceuticals Announces Ifenprodil Reduced Interleukin GlobeNewswire Inc

May 11, 2021

07:01AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that it has reached 50% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil). GlobeNewswire Inc

Apr 26, 2021

08:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, announces that it has filed an end of Phase 2 meeting request (EOP2) with the U.S. Food and Drug Administration (FDA), based on the completion of the Phase 2b part of its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil). GlobeNewswire Inc

Apr 8, 2021

07:00AM EDT Algernon Pharmaceuticals to File End-of-Phase 2 Meeting Request GlobeNewswire Inc

Apr 6, 2021

11:39AM EDT Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree Benzinga

08:00AM EDT Algernon Pharmaceuticals Announces Appointment of Global Expert Dr GlobeNewswire Inc

Mar 31, 2021

08:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce topline data from the Phase 2b part of its Phase 2b/3 COVID-19 trial of NP-120 (Ifenprodil). GlobeNewswire Inc

Mar 29, 2021

07:02AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that it has been added to theHorizons Psychedelic Stock Index ETF (PSYK) in its first quarterly rebalance of holdings. GlobeNewswire Inc

Mar 17, 2021

07:00AM EDT Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request GlobeNewswire Inc

Mar 11, 2021

07:41AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, announces that it expects to report its topline results for the Phase 2b part of its Phase 2b/3 COVID-19 trial of Ifenprodil, in the last week of March 2021. GlobeNewswire Inc

Mar 5, 2021

07:32PM EST Algernon Pharmaceuticals Announces Increase and Close of Private GlobeNewswire Inc

Mar 3, 2021

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, is pleased to announce that Algernons CEO Christopher J. Moreau and DMT Consultant Dr. David Nutt DM, FRCP, FRCPSYCH, FSB, FMEDSCI will be discussing the Companys DMT Stroke Clinical Research Program on an upcoming BioPub webcast. GlobeNewswire Inc

Mar 2, 2021

10:18PM EST Algernon Pharmaceuticals Announces Private Placement GlobeNewswire Inc

Mar 1, 2021

08:00AM EST Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program GlobeNewswire Inc

07:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that it has appointed Dr. Christopher Bryan PhD as Vice President, Research & Operations and Dr. Ahmad Khalil MD, PhD as the Companys Chief Medical Officer. GlobeNewswire Inc

Feb 25, 2021

07:00AM EST Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital GlobeNewswire Inc

Feb 19, 2021

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, announces that it has awarded the contract to manufacture the active pharmaceutical ingredient and finished product for its formulation of AP-188 (N,N-Dimethyltryptamine or DMT), to Canadian-based Dalton Pharma Services (Dalton). GlobeNewswire Inc

Feb 17, 2021

09:06AM EST Enhancing Drug Delivery Systems With Lexaria's Technology Benzinga

07:48AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to provide an update on the final data set of the Phase 2b part of the Phase 2b/3 COVID-19 Ifenprodil study. GlobeNewswire Inc

Feb 10, 2021

07:00AM EST Algernon Pharmaceuticals Considers Adding Lung Scarring as an GlobeNewswire Inc

Feb 9, 2021

03:21PM EST Psyched: Boston Suburbs Decriminalize Psilocybin, Delic Begins Psychedelic Treatments, Australia Denies Legalization Benzinga

Feb 8, 2021

08:05AM EST Algernon Pharmaceuticals Signs Agreement with Charles River GlobeNewswire Inc

Feb 6, 2021

08:37AM EST Psyched: Boston Suburbs Decriminalize Psilocybin, Delic Begins Psychedelic Treatments, Australia Denies Legalization Benzinga

Feb 3, 2021

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, is pleased to announce that Algernons CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Companys New DMT Stroke Clinical Research Program on an upcoming BioPub webcast. GlobeNewswire Inc

Feb 1, 2021

07:30AM EST Algernon Pharmaceuticals Launches Stroke Treatment Clinical GlobeNewswire Inc

Jan 22, 2021

12:14PM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to provide a final summary of the common share purchase warrants of the Company (the NovemberWarrants), that were issued on November 1, 2019. GlobeNewswire Inc

Jan 19, 2021

12:00PM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to provide a reminder to the market that the common share purchase warrants of the Company that were issued on November 1, 2019 (the NovemberWarrants), have had their expiry date accelerated to January 21, 2021. GlobeNewswire Inc

08:03AM EST Algernon Pharmaceuticals Receives Green Light from DSMB to Conduct GlobeNewswire Inc

Jan 11, 2021

08:00AM EST Algernon Highlights New Independent Research Review Identifying GlobeNewswire Inc

Jan 7, 2021

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to provide an overview of the Companys primary plans for the upcoming calendar year. GlobeNewswire Inc

Dec 30, 2020

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to provide a summary of the Companys key activities this past calendar year. GlobeNewswire Inc

Dec 24, 2020

11:43AM EST Algernon Pharmaceuticals Announces Last Patient Out in GlobeNewswire Inc

Dec 23, 2020

07:41PM EST Algernon Pharmaceuticals Announces Acceleration of Expiry Date of GlobeNewswire Inc

Dec 21, 2020

08:00AM EST Algernon CEO and CSO to Discuss COVID-19 Study Interim Data GlobeNewswire Inc

Dec 17, 2020

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to provide additional information on its interim data report for the Phase 2b part of the Companys Phase 2b/3 clinical study of Ifenprodil for COVID-19. GlobeNewswire Inc

Dec 16, 2020

07:44PM EST Algernon CEO and CSO to Discuss COVID-19 Interim Data Results GlobeNewswire Inc

Dec 15, 2020

08:16AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to report, in a descriptive format, positive trending interim data for the Phase 2b part of the Companys Phase 2b/3 clinical study of Ifenprodil for COVID-19. GlobeNewswire Inc

Nov 30, 2020

08:00AM EST Algernon Pharmaceuticals Announces Enrollment of Final Patient in GlobeNewswire Inc

Nov 23, 2020

07:30AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 154 patients in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. GlobeNewswire Inc

Nov 16, 2020

08:00AM EST Algernon Pharmaceuticals Announces Receipt of Refundable Tax GlobeNewswire Inc

Nov 13, 2020

08:00AM EST Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon), a clinical stage pharmaceutical development company, is pleased to announce that it will be providing an update on its Ifenprodil Phase 2 human clinical studies presented by Christopher J. Moreau, CEO and Dr. Mark Williams, CSO and hosted by Dr. KSS MD PhD. GlobeNewswire Inc

Nov 9, 2020

08:00AM EST Algernon Pharmaceuticals Announces Plans to Provide Interim Data GlobeNewswire Inc

Oct 30, 2020

08:00AM EDT Algernon Pharmaceuticals Announces Green Light From Data and GlobeNewswire Inc

Oct 13, 2020

08:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that it has reached 25% of its enrollment target for its Phase 2 idiopathic pulmonary fibrosis (IPF) and chronic cough clinical study of its re-purposed drug NP-120 (Ifenprodil). GlobeNewswire Inc

Oct 9, 2020

08:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the Company or Algernon) a clinical stage pharmaceutical development company is pleased to announce that Dr. Mark Swaim, a former practicing physician and researcher has joined the Algernon Medical and Scientific Advisory Board. GlobeNewswire Inc

Oct 2, 2020

08:40AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 75% of its enrollment target, which is 113 patients, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. GlobeNewswire Inc

Sep 29, 2020

08:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 100 patients, which is two thirds of its enrollment target, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. GlobeNewswire Inc

Sep 22, 2020

08:00AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 75 patients, which is 50% of its enrollment target, for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. GlobeNewswire Inc

Sep 16, 2020

08:01AM EDT Algernon Announces Data and Safety Monitoring Board Recommends the GlobeNewswire Inc

Sep 2, 2020

08:31AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce that it has now enrolled 50 patients in its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. GlobeNewswire Inc

Aug 25, 2020

08:00AM EDT Algernon to Provide Update on its Ifenprodil IPF and Chronic Cough GlobeNewswire Inc

Aug 24, 2020

12:37PM EDT Algernon Updates Market on Analyst Coverage by Mackie Research GlobeNewswire Inc

07:00AM EDT Algernon Announces Research Analyst Coverage by Mackie Research GlobeNewswire Inc

Aug 17, 2020

08:00AM EDT Algernon CEO Presents Corporate Update Featured on BioPub Webcast GlobeNewswire Inc

Aug 13, 2020

08:15AM EDT Algernon Pharmaceuticals Inc.(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the Company or Algernon) a clinical stage pharmaceutical development company, is pleased to announce that it has enrolled its first patient from the U.S. for its multinational Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. GlobeNewswire Inc

Aug 5, 2020

01:58PM EDT Algernon Announces Enrollment of First Patient in 2b/3 Human Study GlobeNewswire Inc

08:37AM EDT Algernon Announces First Patient Dosed in Phase 2 IPF and Chronic GlobeNewswire Inc

Jul 21, 2020

08:01AM EDT Algernon Highlights UT Dallas Research Study Identifying GlobeNewswire Inc

Jul 16, 2020

08:01AM EDT Algernon Announces First U.S. Clinical Trial Site in Florida for GlobeNewswire Inc

Share